Tesofensine is an experimental weight loss drug that suppresses appetite by raising brain levels of three neurotransmitters at once. It started life as a candidate for Alzheimer’s and Parkinson’s disease, failed those trials, and got a second life when researchers noticed that overweight patients on it kept losing weight.<\/p>\n
That origin story matters. Tesofensine was never designed as a diet drug, and it still carries the stimulant-leaning side effect profile you would expect from a triple reuptake inhibitor. It is also not a peptide, despite often being sold next to peptides. It is a small synthetic molecule.<\/p>\n
This guide walks through what tesofensine is, how strong the human evidence actually is, the doses used in trials, the side effects worth taking seriously, and where it sits legally in 2026. The short version: the weight loss numbers are real and large, but the drug is still investigational and the safety questions are not fully answered.<\/p>\n
At TrimRx, we think understanding the full picture, including the gaps, is the first step toward a health plan that actually fits you. If you want to see whether a personalized, supervised program makes sense for you, you can take our free assessment quiz.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Tesofensine is a centrally acting triple monoamine reuptake inhibitor.<\/strong> It blocks the presynaptic reuptake of serotonin, dopamine, and noradrenaline, which raises their levels in brain regions that control hunger and satiety. It was originally coded NS2330 during its years as a neurology candidate.<\/p>\n Quick Answer: Tesofensine is an investigational triple monoamine reuptake inhibitor (it blocks reuptake of serotonin, dopamine, and noradrenaline). It is not a peptide and not FDA approved.<\/p>\n It is an oral small molecule, taken once daily, with a long half-life of roughly nine days. That long half-life means steady blood levels but also slow clearance if side effects appear. Tesofensine is not a hormone, not a GLP-1 drug, and not a peptide.<\/p>\n The compound is owned by Saniona, a Danish biotech, and licensed to Productos Medix in Mexico for obesity. Outside of clinical trials and pending applications, it has no approved consumer form.<\/p>\n Tesofensine reduces appetite by increasing dopamine, noradrenaline, and serotonin signaling in the hypothalamus, the brain’s hunger control center.<\/strong> Animal work (Hansen et al., 2013, in the diet-induced obese rat) showed appetite suppression driven mainly through dopamine D1 receptor and alpha-1 adrenoceptor pathways.<\/p>\n There appear to be two layers to the effect. The first is straightforward appetite suppression, so people eat less. The second is a possible boost to fat oxidation and resting energy expenditure, meaning the body may burn slightly more. The dopamine effect may also blunt the reward or pleasure of eating, which is why some users report food simply becoming less interesting.<\/p>\n This is a different mechanism from GLP-1 drugs like Wegovy\u00ae or Zepbound\u00ae, which slow gastric emptying and act on gut-brain satiety hormones. Tesofensine is closer to a stimulant-class appetite suppressant in how it feels day to day.<\/p>\n The early animal work also found that tesofensine reversed low forebrain dopamine levels seen in diet-induced obese rats, which researchers linked to its appetite effect. In simpler terms, obesity in those models was associated with blunted dopamine signaling, and tesofensine appeared to restore some of that signaling. Whether this fully translates to humans is not settled, but it gives a plausible biological reason the drug curbs the drive to eat.<\/p>\n In the main phase 2 trial, the 0.5 mg dose produced about 9.2% mean weight loss over 24 weeks, versus 2.0% on placebo.<\/strong> The 1.0 mg dose pushed mean loss to 10.6%, but with more side effects. These figures come from Astrup and colleagues, published in the Lancet in 2008.<\/p>\n That placebo-subtracted effect was roughly double what the weight loss drugs available at the time delivered. A later phase 3 program run by Medix in Mexico, involving 372 patients, reported about 10% average weight loss at 24 weeks, with more than half of patients losing more than 10%.<\/p>\n One honest caveat: the original 2008 Lancet paper received a formal expression of concern from the journal’s editors in 2013 over trial irregularities at two of the five study sites. The headline numbers are still widely cited, but that flag is part of the record and worth knowing.<\/p>\n It is also worth putting the trial length in context. The phase 2 and phase 3 results came over 24 weeks. Most modern obesity drug approvals rest on a year or more of data, which captures both deeper weight loss and longer safety follow-up. Tesofensine simply has not been tested at that scale in the published literature, so its long-run risk and benefit profile is less certain than the approved GLP-1 medications.<\/p>\n The studied dose range is 0.25 mg to 1.0 mg once daily, with 0.5 mg the best-supported choice.<\/strong> The 0.5 mg dose hit the sweet spot in trials: strong weight loss with a more manageable side effect profile than 1.0 mg.<\/p>\n Clinics that offer tesofensine off-label or in research settings typically start low, often at 0.25 mg, and titrate up slowly over weeks while watching blood pressure and heart rate. The long half-life means dose changes take time to fully show up, so patience matters.<\/p>\n There is no FDA-sanctioned dosing label because the drug is not approved. Any dosing you see is drawn from the trial protocols, not from a regulatory standard.<\/p>\n The most common side effects are dry mouth, insomnia, constipation, and changes in mood.<\/strong> The bigger safety signals are increased heart rate and blood pressure, which is the main reason the drug remains investigational rather than approved.<\/p>\n In the phase 2 data, the 0.5 mg dose raised heart rate and blood pressure meaningfully. Researchers later studied pairing tesofensine with a beta-blocker (metoprolol) to blunt the cardiovascular effects while keeping the appetite suppression, an approach Saniona has pursued for a rarer condition called hypothalamic obesity.<\/p>\n Because tesofensine touches dopamine and serotonin, mood and psychiatric effects are a real concern, including agitation, anxiety, and sleep disruption. Anyone with a cardiac history, uncontrolled blood pressure, or a psychiatric condition is a poor candidate.<\/p>\n The cardiovascular signal is the central reason regulators have moved cautiously. A drug that delivers strong weight loss but nudges blood pressure and heart rate upward has to prove that the metabolic benefit outweighs the cardiac cost over time, especially in a population that often already has hypertension. That trade-off is exactly what the tesofensine plus metoprolol combination work has tried to address, by adding a beta-blocker to hold the heart rate down while keeping the appetite effect.<\/p>\n No. Tesofensine is not approved by the FDA or by any major regulator as of mid-2026. It remains an investigational compound.<\/p>\n The closest it has come to market is in Mexico, where Medix filed for approval with Cofepris in May 2023 and submitted an updated package in 2024. As of the most recent public updates, that application is still pending and had not been approved. Saniona has also pursued tesofensine, combined with metoprolol, for hypothalamic obesity, a separate and narrower path.<\/p>\n In the United States, tesofensine is sometimes sold by compounding pharmacies or research suppliers, but it has no FDA approval and no standardized quality oversight in those channels. That is a meaningful difference from FDA-cleared options.<\/p>\n Tesofensine works through brain neurotransmitters, while GLP-1 drugs like semaglutide and tirzepatide work through gut hormone pathways.<\/strong> The GLP-1 class has far more extensive safety data and full FDA approval behind it.<\/p>\n In head-to-head terms on weight loss, semaglutide in the STEP 1 trial (Wilding 2021, NEJM) produced about 14.9% mean weight loss at 68 weeks, and tirzepatide in SURMOUNT-1 (Jastreboff 2022, NEJM) reached up to about 20.9% at 72 weeks. Tesofensine’s roughly 9 to 10% came over a shorter 24-week window, so direct comparison is imperfect, but the GLP-1 ceiling is higher and far better documented.<\/p>\n The practical difference: GLP-1 medications are approved, supervised, and available through legitimate telehealth, including compounded semaglutide and tirzepatide. Tesofensine is not.<\/p>\n Anyone with cardiovascular disease, high blood pressure, arrhythmia, or a psychiatric condition should avoid tesofensine.<\/strong> Its stimulant-like effects on heart rate, blood pressure, and mood make it risky for these groups.<\/p>\n It is also not appropriate during pregnancy or breastfeeding, for anyone under 18, or for people on MAO inhibitors or certain antidepressants, given the serotonin and dopamine activity. Combining it with other stimulants compounds the cardiovascular risk.<\/p>\n Because it is investigational, even healthy candidates should approach it only under genuine medical supervision with blood pressure and heart rate monitoring, not as a self-directed purchase.<\/p>\n Key Takeaway: It is not approved anywhere as of mid-2026. A Mexican application by Medix is still pending with Cofepris after filings in 2023 and 2024.<\/p>\n Most user reports describe a clear drop in appetite within the first one to two weeks, along with a stimulant-like edge.<\/strong> Because the drug raises noradrenaline and dopamine, people often note more alertness, sometimes jitteriness, and a reduced interest in food rather than the fullness sensation GLP-1 users describe.<\/p>\n The experience is closer to a strong appetite suppressant than to a satiety hormone. Some people find the energy lift useful. Others find the sleep disruption and dry mouth hard to live with, especially at the 1.0 mg dose. The long half-life means whatever you feel tends to be steady rather than coming in peaks and crashes.<\/p>\n This is also why slow titration matters. Starting at 0.25 mg lets the body adjust to the cardiovascular and sleep effects before pushing toward the more effective 0.5 mg dose. Jumping straight to a high dose is where tolerability problems usually show up.<\/p>\n The honest answer is that the long-term maintenance data is thin.<\/strong> The TIPO-4 study, a 48-week open-label extension of the original phase 2 trial, suggested weight loss was sustained while patients kept taking the drug. What happens after stopping is much less documented.<\/p>\n This is a pattern across nearly all pharmacological weight loss, including the GLP-1 class: when the medication stops, appetite tends to return and some regain is common unless habits and supports are in place. There is no published evidence that tesofensine is an exception.<\/p>\n Treat any weight loss drug as a tool that works while you use it, paired with diet, activity, and behavior changes that you can keep up independently. Tesofensine has not been shown to rewire long-term appetite on its own.<\/p>\n Tesofensine’s activity on serotonin, dopamine, and noradrenaline creates real interaction risks.<\/strong> Combining it with MAO inhibitors, SSRIs, SNRIs, or other serotonergic drugs raises the theoretical risk of serotonin syndrome, and stacking it with stimulants or decongestants compounds cardiovascular strain.<\/p>\n Alcohol and poor sleep can worsen the mood and anxiety effects. Caffeine on top of tesofensine’s own stimulant action can push heart rate and jitteriness higher than expected. None of these combinations have been formally studied in large trials, so caution is the default.<\/p>\n This interaction profile is one more reason tesofensine belongs under medical supervision with a full medication review, not in a self-directed regimen.<\/p>\n Tesofensine was first developed by the Danish company NeuroSearch under the code NS2330, aimed at neurodegenerative disease.<\/strong> After it underperformed in Alzheimer’s and Parkinson’s trials, the rights moved to Saniona, another Danish biotech, which refocused it on obesity.<\/p>\n Saniona licensed the obesity rights for Mexico and parts of Latin America to Productos Medix, a large Mexican pharmaceutical maker. Medix ran the phase 3 program and filed for regulatory approval in Mexico. Saniona has separately developed a tesofensine plus metoprolol combination, branded Tesomet, for rarer conditions such as hypothalamic obesity and Prader-Willi syndrome.<\/p>\n Knowing the developers matters because it tells you where legitimate supply could eventually come from. Any tesofensine sold today in the US is outside these official channels, since no approved product exists here.<\/p>\n Before considering tesofensine, ask whether an approved option could meet your goal first, and whether your heart and mental health history make you a safe candidate.<\/strong> Those two questions screen out most of the risk.<\/p>\n A few specific things to check with a clinician: your resting blood pressure and heart rate, any history of arrhythmia, anxiety, depression, or bipolar disorder, and every medication and supplement you take that touches serotonin or acts as a stimulant. You should also ask about monitoring, because tesofensine use without regular blood pressure checks is not safe practice.<\/p>\n Finally, ask about source and quality. With no FDA-approved product, you are relying on a compounding pharmacy or research supplier, and quality varies. That uncertainty is a real part of the risk calculation, not a footnote.<\/p>\n Tesofensine is taken orally once a day, usually in the morning to limit its effect on sleep.<\/strong> Because it is a once-daily oral compound with a long half-life, timing is less about peaks and more about consistency, so taking it at the same time each day keeps levels steady.<\/p>\n In research and compounding settings it shows up as capsules or as a powder for reconstitution. Oral capsules are the format used in the human trials. If a supplier offers an injectable or sublingual version, that is outside the studied route and adds another layer of uncertainty about dose and absorption.<\/p>\n Storage follows standard small-molecule rules: keep it cool, dry, and out of direct light, and away from children. None of this substitutes for the bigger point, which is that tesofensine has no approved consumer product, so any handling instructions come from suppliers rather than a regulated label.<\/p>\n If your goal is meaningful, sustained weight loss with a clear safety record, the evidence still favors the approved GLP-1 options over an investigational drug like tesofensine.<\/strong> TrimRX offers physician-supervised programs built around compounded semaglutide and tirzepatide, personalized to your health profile.<\/p>\n We are honest about the trade-offs. Tesofensine’s numbers are eye-catching, but it carries open cardiovascular and psychiatric questions and no FDA approval. A supervised GLP-1 program gives you strong results on a foundation of real-world safety data. If you want to find out what fits you, the free TrimRX assessment quiz is a low-pressure place to start.<\/p>\n Bottom line: Typical research and clinic doses sit between 0.25 mg and 1.0 mg once daily, with 0.5 mg the most studied.<\/p>\n No. Tesofensine is a small synthetic molecule, specifically a triple monoamine reuptake inhibitor. It is often grouped with research peptides commercially, but chemically it is not one. This distinction matters for how it works and how it is regulated.<\/p>\n Tesofensine has a long half-life of roughly nine days, so it builds up to steady levels with daily dosing and clears slowly. That long tail means side effects can persist for a while after stopping, and dose changes take time to fully register.<\/p>\n In trials, yes. The 0.5 mg dose produced about 9.2% mean weight loss over 24 weeks in the phase 2 study, and a Mexican phase 3 program reported around 10%. The numbers are strong, though the drug is still investigational and one early trial carried an editorial expression of concern.<\/p>\n There is no FDA-approved tesofensine product in the US. It is sometimes sold through compounding pharmacies or research suppliers, but those channels lack FDA approval and standardized quality oversight. Approved options like compounded semaglutide and tirzepatide are the safer route.<\/p>\n Semaglutide has stronger weight loss data (about 14.9% in STEP 1) and full FDA approval, while tesofensine delivered around 9 to 10% in shorter trials and remains investigational. They also work differently, with tesofensine acting on brain neurotransmitters and semaglutide on gut hormone pathways.<\/p>\n The 0.5 mg once-daily dose is the best-studied balance of effect and tolerability. Higher doses like 1.0 mg increase weight loss slightly but worsen side effects, especially raised heart rate and blood pressure. Any use should be medically supervised with cardiovascular monitoring.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Tesofensine is an experimental weight loss drug that suppresses appetite by raising brain levels of three neurotransmitters at once.<\/p>\n","protected":false},"author":11,"featured_media":107152,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[19],"tags":[],"class_list":["post-107153","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevity"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/107153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=107153"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/107153\/revisions"}],"predecessor-version":[{"id":108413,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/107153\/revisions\/108413"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/107152"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=107153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=107153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=107153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How Does Tesofensine Cause Weight Loss?<\/h2>\n
How Much Weight Do People Lose on Tesofensine?<\/h2>\n
What Doses of Tesofensine Are Used?<\/h2>\n
What Are the Side Effects of Tesofensine?<\/h2>\n
Is Tesofensine FDA Approved?<\/h2>\n
How Does Tesofensine Compare to GLP-1 Drugs?<\/h2>\n
Who Should Avoid Tesofensine?<\/h2>\n
What Does Tesofensine Feel Like Day to Day?<\/h2>\n
Does the Weight Stay Off After Stopping Tesofensine?<\/h2>\n
How Does Tesofensine Interact with Other Substances?<\/h2>\n
Where Does Tesofensine Come From and WHO Develops It?<\/h2>\n
What Should You Ask Before Trying Tesofensine?<\/h2>\n
How Is Tesofensine Taken and Stored?<\/h2>\n
The Path Forward with TrimRx<\/h2>\n
FAQ<\/h2>\n
Is Tesofensine a Peptide?<\/h3>\n
How Long Does Tesofensine Stay in Your System?<\/h3>\n
Does Tesofensine Work for Weight Loss?<\/h3>\n
Can I Buy Tesofensine Legally in the US?<\/h3>\n
How Does Tesofensine Compare to Semaglutide?<\/h3>\n
What Is the Safest Tesofensine Dose?<\/h3>\n